Member Spotlight - August 22, 2023
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In August, we spoke with Shekhar Natarajan, Vice President – EU Regulatory Affairs, Dyne Therapeutics. Shekhar Natarajan is Vice President-… read more
Member Spotlight / News - April 24, 2023
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In March, we spoke with Fabien Roy, Partner, Hogan Lovells Life Sciences practice. Fabien Roy is a partner at Hogan… read more
Member Spotlight / News - February 20, 2023
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In February, we spoke with Anne Dagallier, Chief Business Officer of Enterome. Anne Dagallier joined Enterome in 2021 as… read more
Member Spotlight / News - June 24, 2022
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In June, we spoke with Julien Patris, Head of Policy – International Markets at Alnylam Pharmaceuticals. Julien Patris is Country… read more
Member Spotlight / News - May 6, 2022
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In April, we spoke with Malte Peters, M.D., Chief Research and Development Officer, MorphoSys. Dr. Malte Peters joined MorphoSys in… read more
News - April 26, 2021
On 7 May, the European Commission opened its public consultation on the revision of EU rules on medicines for children and rare diseases. The consultation, aimed at stakeholders and members of the general public, including patients and doctors, will explore several options to address the shortcomings… read more
News / Press Releases - March 3, 2021
A large consortium of European health-related stakeholders, including industry players, academia, healthcare professionals and patients, share their satisfaction on the draft adequacy decision on the UK data protection regime issued by the European Commission on 19th February 2021. Protecting the benefits of the free flow… read more
News - January 1, 2021
Following a successful launch event, the TRANSFORM MEP Interest Group, a multi-stakeholder alliance of Members of European Parliament, patient groups, academia and industry, published two important documents to lay the foundations of an open discussion on key priorities for gene and cell therapies, namely a… read more
News - December 2, 2020
On 8 December, the European Alliance for Transformative Therapies, a broad alliance of Members of European Parliament, patient groups, European Reference Networks, academia and industry, will be officially launched in a virtual meeting from 16.00 to 17.30. The Alliance, supported by MEPs Claudia Gamon (RE,… read more
EUCOPE Resources / News / Press Releases - November 25, 2020
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information